AstraZeneca Pharmaceuticals, LP
Registered Principal Details
Business Or Interest:
Research, development and sale of biopharmaceuticals.
Lobbying Interests:
Pharma drug pricing and affordability. PBM reform. Cancer and Chronic Disease Screenings. Biomarker testing. Health Equity and Sustainability, PFAS. Matters related to regulation of prescription drugs, health care, health insurance, Medicaid issues, and pharmacy issues.
CEO Name:
Pascal Soriot
Research, development and sale of biopharmaceuticals.
Lobbying Interests:
Pharma drug pricing and affordability. PBM reform. Cancer and Chronic Disease Screenings. Biomarker testing. Health Equity and Sustainability, PFAS. Matters related to regulation of prescription drugs, health care, health insurance, Medicaid issues, and pharmacy issues.
CEO Name:
Pascal Soriot
Contact
KB
Kelly Burgeson
1800 Concord Pike
Wilmington, DE 19850
(203) 482-2347
compliance_WI_az@multistate.us
https://www.astrazeneca.com/
1800 Concord Pike
Wilmington, DE 19850
(203) 482-2347
compliance_WI_az@multistate.us
https://www.astrazeneca.com/
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 173
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
4/16/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date4/16/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Assembly Bill 263
Relating to: coverage of breast cancer screenings by the Medical Assistance program and health insurance policies and plans. (FE)
Bill Text and History
7/31/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: coverage of breast cancer screenings by the Medical Assistance program and health insurance policies and plans. (FE)
Bill Text and History
For
Notification Date7/31/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Senate Bill 203
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
4/21/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date4/21/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Senate Bill 264
Relating to: coverage of breast cancer screenings by the Medical Assistance program and health insurance policies and plans. (FE)
Bill Text and History
7/31/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: coverage of breast cancer screenings by the Medical Assistance program and health insurance policies and plans. (FE)
Bill Text and History
For
Notification Date7/31/2025
First Communication Date
7/22/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Budget Bill Subjects
Biennial budget bill treatment of matter relating to
Health Services: Departmentwide
Health Services: Departmentwide
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Biennial budget bill treatment of matter relating to
Health Services: Medicaid Services
Health Services: Medicaid Services
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Biennial budget bill treatment of matter relating to
Insurance: Supervision of the Insurance Industry
Insurance: Supervision of the Insurance Industry
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Biomarker Testing
Biomarker Testing
Action Intended To Affect
Legislative matter
Notification Date
6/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Legislative matter
Notification Date
6/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to
Data Privacy
Data Privacy
Action Intended To Affect
Legislative matter
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Legislative matter
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to
Rare Diseases
Rare Diseases
Action Intended To Affect
Legislative matter
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Legislative matter
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to
Regulation of Prescription Drugs
Regulation of Prescription Drugs
Action Intended To Affect
Legislative matter
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Legislative matter
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to
2025-27 Biennial Budget Bill
2025-27 Biennial Budget Bill
Notification Date
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
4/16/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Total Lobbying Effort
| 2025 January - June |
Total | |
|---|---|---|
| Total Lobbying Expenditures | 2025 January - June $1,688.00 |
Total $1,688.00 |
| Total Hours Communicating | 2025 January - June 0.75 |
Total 0.75 |
| Total Hours Other | 2025 January - June 8.50 |
Total 8.50 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
|---|---|---|---|---|
| 2025 January - June 10% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 11% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
|---|---|---|---|---|
| 2025 January - June 10% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 11% |
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
|---|---|---|---|---|
| 2025 January - June 20% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 20% |
Minor Efforts
(Time spent on matters each of which accounted for less than 10% of the organization's lobbying.)
Other Matters
No other matters found.